20/20 Biolabs, Inc. Common Stock
20/20 Biolabs, Inc. Common Stock Fundamental Analysis
20/20 Biolabs, Inc. Common Stock (AIDX) shows moderate financial fundamentals with a PE ratio of -4.28, profit margin of -2.17%, and ROE of 21.70%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 684.5/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze AIDX's fundamental strength across five key dimensions:
Efficiency Score
WeakAIDX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentAIDX trades at attractive valuation levels.
Growth Score
WeakAIDX faces weak or negative growth trends.
Financial Health Score
ModerateAIDX shows balanced financial health with some risks.
Profitability Score
WeakAIDX struggles to sustain strong margins.
Key Financial Metrics
Is AIDX Expensive or Cheap?
P/E Ratio
AIDX trades at -4.28 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, AIDX's PEG of -0.04 indicates potential undervaluation.
Price to Book
The market values 20/20 Biolabs, Inc. Common Stock at -0.46 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 124.62 times EBITDA. This signals the market has high growth expectations.
How Well Does AIDX Make Money?
Net Profit Margin
For every $100 in sales, 20/20 Biolabs, Inc. Common Stock keeps $-2.17 as profit after all expenses.
Operating Margin
Core operations generate -2.14 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $21.70 in profit for every $100 of shareholder equity.
ROA
20/20 Biolabs, Inc. Common Stock generates $-0.05 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
20/20 Biolabs, Inc. Common Stock generates limited operating cash flow of $-544.41K, signaling weaker underlying cash strength.
Free Cash Flow
20/20 Biolabs, Inc. Common Stock generates weak or negative free cash flow of $-544.41K, restricting financial flexibility.
FCF Per Share
Each share generates $-0.11 in free cash annually.
FCF Yield
AIDX converts -5.95% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-4.28
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.04
vs 25 benchmark
P/B Ratio
Price to book value ratio
-0.46
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.42
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-66.79
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.60
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.22
vs 25 benchmark
ROA
Return on assets percentage
-0.00
vs 25 benchmark
ROCE
Return on capital employed
-0.00
vs 25 benchmark
How AIDX Stacks Against Its Sector Peers
| Metric | AIDX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -4.28 | 28.45 | Better (Cheaper) |
| ROE | 21.70% | 763.00% | Weak |
| Net Margin | -217.45% | -45265.00% (disorted) | Weak |
| Debt/Equity | -66.79 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 0.60 | 2795.60 | Weak Liquidity |
| ROA | -0.05% | -16588.00% (disorted) | Weak |
AIDX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews 20/20 Biolabs, Inc. Common Stock's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation